Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: Retrospective data from selected obese menopausal symptomatic women

Gynecological Endocrinology

Volumn 29, Issue 2, 2013, Pages 156-159

  Morelli, Michele ^a   Di Cello, Annalisa ^a   Venturella, Roberta ^a   Mocciaro, Rita ^a   D'Alessandro, Pietro ^a   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Endometrial cancer; Endometrial hyperplasia; Levonorgestrel intrauterine system; Obesity; Postmenopausal

Indexed keywords

LEVONORGESTREL;

ADULT; AGED; BODY MASS; CANCER GROWTH; CANCER PREVENTION; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; OBESITY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYMPTOM; TREATMENT INDICATION; UTERUS BLEEDING;

ADMINISTRATION, INTRAVAGINAL; AGED; BODY MASS INDEX; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LEVONORGESTREL; MIDDLE AGED; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RECURRENCE; RETROSPECTIVE STUDIES; RISK; UTERINE HEMORRHAGE;

EID: 84871427255     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.730579     Document Type: Review

References (26)

1. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-378. (Pubitemid 38525783)
2. Hunter JE, Tritz DE, Howell MG, DePriest PD, Gallion HH, Andrews SJ, Buckley SB, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994;55:66-71.
3. Anderson JN, Peck EJ Jr, Clark JH. Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 1975;96:160-167.
4. King RJ, Whitehead MI, Campbell S, Minardi J. Effect of estrogen and progestin treatments on endometria from postmenopausal women. Cancer Res 1979;39:1094-1101. (Pubitemid 9135140)
5. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575-580. (Pubitemid 40271225)
6. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788-792.
7. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 2008;168:563-70; discussion 571.
8. Viola AS, Gouveia D, Andrade L, Aldrighi JM, Viola CF, Bahamondes L. Prevalence of endometrial cancer and hyperplasia in non-symptomatic overweight and obese women. Aust N Z J Obstet Gynaecol 2008;48:207-213. (Pubitemid 351441618)
9. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-412. (Pubitemid 15031667)
10. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413-425.
11. Mansour D. Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007;21:1007-1021. (Pubitemid 350177608)
12. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-213. (Pubitemid 46771029)
13. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297-1298. (Pubitemid 36589125)
14. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-175.
15. Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 2011;14:622-632.
16. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011;18:75-80.
17. Leslie KK, Thiel KW, Yang S. Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices. Obstet Gynecol 2012;119:419-420.
18. ROGERS J, MITCHELL GW Jr. The relation of obesity to menstrual disturbances. N Engl J Med 1952;247:53-55.
19. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543. (Pubitemid 36020003)
20. Matteson KA, Abed H, Wheeler TL 2nd, Sung VW, Rahn DD, Schaffer JI, Balk EM; Society of Gynecologic Surgeons Systematic Review Group. A systematic review comparing hysterectomy with less-invasive treatments for abnormal uterine bleeding. J Minim Invasive Gynecol 2012;19:13-28.
21. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;4:CD002126.
22. Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol 2008;111:547-549. (Pubitemid 351156496)
23. Andersson K, Stadberg E, Mattsson LA, Rybo G, Samsioe G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 months of treatment. Int J Fertil Menopausal Stud 1996;41:476-483.
24. Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999;72:161-163. (Pubitemid 29300279)
25. Varila E, Wahlstr T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-973. (Pubitemid 33031324)
26. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653-2660. (Pubitemid 41222525)